Anoro Ellipta Approval Status 
- FDA approved: No
- Brand name: Anoro Ellipta
- Generic name: umeclidinium bromide and vilanterol
- Company: GlaxoSmithKline plc (GSK) and Theravance, Inc.
- Treatment for: COPD
Anoro Ellipta (umeclidinium bromide and vilanterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) combination in development for the treatment of COPD.
FDA Approval Status for Anoro Ellipta
| Date | Article |
|---|---|
| Feb 19, 2013 | GSK and Theravance Announce FDA Acceptance of New Drug Application Submission in the US for Anoro Ellipta for COPD |
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
